Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapinarof in Pediatric Plaque Psoriasis
NCT05172726Phase 3Active, not recruiting
- Sponsor
- Organon & Co.
- Start
- Dec 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tapinarof in plaque psoriasis, sponsored by Organon & Co. Primary endpoints: Adverse Events and Serious Adverse Events at 53 weeks, Clinically Significant Laboratory Test Abnormalities at 53 weeks and 3 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
tapinarof
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05172726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172726.